Literature DB >> 31758746

Multi-site reproducibility of a human immunophenotyping assay in whole blood and peripheral blood mononuclear cells preparations using CyTOF technology coupled with Maxpar Pathsetter, an automated data analysis system.

Charles Bruce Bagwell1, Benjamin Hunsberger1, Beth Hill1, Donald Herbert1, Christopher Bray1, Thirumahal Selvanantham2, Stephen Li2, Jose C Villasboas3, Kevin Pavelko3, Michael Strausbauch3, Adeeb Rahman4, Gregory Kelly4, Shahab Asgharzadeh5, Azucena Gomez-Cabrero5, Gregory Behbehani6, Hsiaochi Chang6, Justin Lyberger6, Ruth Montgomery7, Yujiao Zhao7, Margaret Inokuma1, Ofir Goldberger8, Greg Stelzer8.   

Abstract

High-dimensional mass cytometry data potentially enable a comprehensive characterization of immune cells. In order to positively affect clinical trials and translational clinical research, this advanced technology needs to demonstrate a high reproducibility of results across multiple sites for both peripheral blood mononuclear cells (PBMC) and whole blood preparations. A dry 30-marker broad immunophenotyping panel and customized automated analysis software were recently engineered and are commercially available as the Fluidigm® Maxpar® Direct™ Immune Profiling Assay™. In this study, seven sites received whole blood and six sites received PBMC samples from single donors over a 2-week interval. Each site labeled replicate samples and acquired data on Helios™ instruments using an assay-specific acquisition template. All acquired sample files were then automatically analyzed by Maxpar Pathsetter™ software. A cleanup step eliminated debris, dead cells, aggregates, and normalization beads. The second step automatically enumerated 37 immune cell populations and performed label intensity assessments on all 30 markers. The inter-site reproducibility of the 37 quantified cell populations had consistent population frequencies, with an average %CV of 14.4% for whole blood and 17.7% for PBMC. The dry reagent coupled with automated data analysis is not only convenient but also provides a high degree of reproducibility within and among multiple test sites resulting in a comprehensive yet practical solution for deep immune phenotyping.
© 2019 International Clinical Cytometry Society.

Entities:  

Keywords:  cytometry automation; cytometry standardization; kits; percentage precision

Mesh:

Year:  2019        PMID: 31758746      PMCID: PMC7543682          DOI: 10.1002/cyto.b.21858

Source DB:  PubMed          Journal:  Cytometry B Clin Cytom        ISSN: 1552-4949            Impact factor:   3.058


  15 in total

1.  Automated analysis of flow cytometric data for CD34+ stem cell enumeration using a probability state model.

Authors:  Donald J Herbert; David T Miller; C Bruce Bagwell
Journal:  Cytometry B Clin Cytom       Date:  2012-07-11       Impact factor: 3.058

2.  Mononuclear phagocytes and marker modulation: when CD16 disappears, CD38 takes the stage.

Authors:  Mario Picozza; Luca Battistini; Giovanna Borsellino
Journal:  Blood       Date:  2013-07-18       Impact factor: 22.113

Review 3.  Standardizing immunophenotyping for the Human Immunology Project.

Authors:  Holden T Maecker; J Philip McCoy; Robert Nussenblatt
Journal:  Nat Rev Immunol       Date:  2012-02-17       Impact factor: 53.106

Review 4.  High-Dimensional Modeling for Cytometry: Building Rock Solid Models Using GemStone™ and Verity Cen-se'™ High-Definition t-SNE Mapping.

Authors:  C Bruce Bagwell
Journal:  Methods Mol Biol       Date:  2018

5.  Probability state modeling of memory CD8⁺ T-cell differentiation.

Authors:  Margaret S Inokuma; Vernon C Maino; C Bruce Bagwell
Journal:  J Immunol Methods       Date:  2013-08-14       Impact factor: 2.303

6.  Multicenter Systems Analysis of Human Blood Reveals Immature Neutrophils in Males and During Pregnancy.

Authors:  Jana Blazkova; Sarthak Gupta; Yudong Liu; Brice Gaudilliere; Edward A Ganio; Christopher R Bolen; Ron Saar-Dover; Gabriela K Fragiadakis; Martin S Angst; Sarfaraz Hasni; Nima Aghaeepour; David Stevenson; Nicole Baldwin; Esperanza Anguiano; Damien Chaussabel; Matthew C Altman; Mariana J Kaplan; Mark M Davis; David Furman
Journal:  J Immunol       Date:  2017-02-08       Impact factor: 5.422

7.  Heparin reduces nonspecific eosinophil staining artifacts in mass cytometry experiments.

Authors:  Adeeb H Rahman; Leticia Tordesillas; M Cecilia Berin
Journal:  Cytometry A       Date:  2016-04-06       Impact factor: 4.355

8.  Automated analysis of GPI-deficient leukocyte flow cytometric data using GemStone™.

Authors:  David T Miller; Benjamin C Hunsberger; C Bruce Bagwell
Journal:  Cytometry B Clin Cytom       Date:  2012-05-04       Impact factor: 3.058

9.  Standardizing Flow Cytometry Immunophenotyping Analysis from the Human ImmunoPhenotyping Consortium.

Authors:  Greg Finak; Marc Langweiler; Maria Jaimes; Mehrnoush Malek; Jafar Taghiyar; Yael Korin; Khadir Raddassi; Lesley Devine; Gerlinde Obermoser; Marcin L Pekalski; Nikolas Pontikos; Alain Diaz; Susanne Heck; Federica Villanova; Nadia Terrazzini; Florian Kern; Yu Qian; Rick Stanton; Kui Wang; Aaron Brandes; John Ramey; Nima Aghaeepour; Tim Mosmann; Richard H Scheuermann; Elaine Reed; Karolina Palucka; Virginia Pascual; Bonnie B Blomberg; Frank Nestle; Robert B Nussenblatt; Ryan Remy Brinkman; Raphael Gottardo; Holden Maecker; J Philip McCoy
Journal:  Sci Rep       Date:  2016-02-10       Impact factor: 4.379

10.  Comparison of CyTOF assays across sites: Results of a six-center pilot study.

Authors:  Michael D Leipold; Gerlinde Obermoser; Craig Fenwick; Katja Kleinstuber; Narges Rashidi; John P McNevin; Allison N Nau; Lisa E Wagar; Virginie Rozot; Mark M Davis; Stephen DeRosa; Giuseppe Pantaleo; Thomas J Scriba; Bruce D Walker; Lars R Olsen; Holden T Maecker
Journal:  J Immunol Methods       Date:  2017-11-23       Impact factor: 2.303

View more
  6 in total

1.  Customizing Maxpar Direct Immune Profiling Assay with Additional Surface Marker and Intracellular Cytokine Staining Workflows for Expanded Mass Cytometry Panels.

Authors:  Carlene Petes; Stephen K H Li; Shariq Mujib; Michelle M Poulin; Noah Saederup; Andrew A Quong; Christina Loh
Journal:  Methods Mol Biol       Date:  2022

2.  Underlying Co-Morbidity Reveals Unique Immune Signatures in Type II Diabetes Patients Infected With SARS-CoV2.

Authors:  Soumya Sengupta; Gargee Bhattacharya; Sanchari Chatterjee; Ankita Datey; Shubham K Shaw; Sandhya Suranjika; Paritosh Nath; Prakash K Barik; Punit Prasad; Soma Chattopadhyay; Rajeeb K Swain; Ajay Parida; Satish Devadas
Journal:  Front Immunol       Date:  2022-04-27       Impact factor: 8.786

3.  Gene signature and immune cell profiling by high-dimensional, single-cell analysis in COVID-19 patients, presenting Low T3 syndrome and coexistent hematological malignancies.

Authors:  Salvatore Sciacchitano; Claudia De Vitis; Michela D'Ascanio; Simonetta Giovagnoli; Chiara De Dominicis; Andrea Laghi; Paolo Anibaldi; Andrea Petrucca; Gerardo Salerno; Iolanda Santino; Rachele Amodeo; Maurizio Simmaco; Christian Napoli; Agostino Tafuri; Arianna Di Napoli; Andrea Sacconi; Valentina Salvati; Gennaro Ciliberto; Maurizio Fanciulli; Giulia Piaggio; Luisa de Latouliere; Alberto Ricci; Rita Mancini
Journal:  J Transl Med       Date:  2021-04-01       Impact factor: 5.531

4.  A streamlined whole blood CyTOF workflow defines a circulating immune cell signature of COVID-19.

Authors:  Daniel Geanon; Brian Lee; Edgar Gonzalez-Kozlova; Geoffrey Kelly; Diana Handler; Bhaskar Upadhyaya; John Leech; Ronaldo M De Real; Manon Herbinet; Assaf Magen; Diane Del Valle; Alexander Charney; Seunghee Kim-Schulze; Sacha Gnjatic; Miriam Merad; Adeeb H Rahman
Journal:  Cytometry A       Date:  2021-02-16       Impact factor: 4.714

5.  Immunomodulating Activity of Pleurotus eryngii Mushrooms Following Their In Vitro Fermentation by Human Fecal Microbiota.

Authors:  Marigoula Vlassopoulou; Nikolaos Paschalidis; Alexandros L Savvides; Georgia Saxami; Evdokia K Mitsou; Evangelia N Kerezoudi; Georgios Koutrotsios; Georgios I Zervakis; Panagiotis Georgiadis; Adamantini Kyriacou; Vasiliki Pletsa
Journal:  J Fungi (Basel)       Date:  2022-03-22

6.  Case report: Bilateral panuveitis resembling Vogt-Koyanagi-Harada disease after second dose of BNT162b2 mRNA COVID-19 vaccine.

Authors:  Tomohito Sato; Ryotaro Nihei; Daisuke Sora; Yoshiaki Nishio; Masaru Takeuchi
Journal:  Front Immunol       Date:  2022-09-29       Impact factor: 8.786

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.